Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain ...
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...
Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...
The latest update is out from Summit Therapeutics ( (SMMT) ).
“Completing enrollment in the first global study for ivonescimab is a credit to the growing belief in the potential for ivonescimab to make a significant difference in the lives of patients ...
The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab. The stock market has been pushing up Summit's stock ...
The company has not yet had any sales of its products. Its first potential drug, ivonescimab, is in phase 3 clinical testing. Ivonescimab works similarly to Merck's pembrolizumab by making cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback